Loading clinical trials...

A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

A Phase III, Randomized, Observer-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Immunogenicity and Safety of a Preventive COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

NCT05572879•EuBiologics Co.,Ltd

View on ClinicalTrials.gov

Summary

This is a phase III, randomized, observer-blind, active-controlled, parallel group, multi-center study to compare the immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 to ChAdOx1 in healthy adults aged 18 years and older

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Individuals aged 18 years and older who voluntarily decide to participate in this study and provide written informed consent
•Female of childbearing potential who agree to use medically allowed methods of contraception during the study period
•Individuals who agrees not to perform blood donation and transfusion during the study period

Exclusion Criteria

•Individual being considered to be confirmed COVID-19
•Direct contact with COVID-19 infected person within 14 days prior to the 1st dose of the IP
•Individuals at high risk of exposure to SARS-CoV-2
•Individuals with clinically significant abnormalities in clinical laboratory tests, ECGs, and chest X-ray during screening
•Individuals with fever within 72 hours prior to the 1st dose of the IP or suspected other infectious disease or symptoms associated with other infectious disease
•Individuals with serious medical or psychiatric disease
•History of SARS-CoV or MERS-CoV infection
•History of allergic reaction or hypersensitivity reactions to any of components of the IP
•History of serious adverse events, serious allergic reaction or serious hypersensitivity reactions to vaccination
•History of receiving organ or bone marrow transplant
+7 more criteria

Locations (1)

Trial site

Manila, Philippines

Key Dates

Start Date

October 1, 2022

Primary Completion Date

June 23, 2023

Completion Date

February 9, 2024

Last Updated

June 17, 2024

Enrollment

2,600

ACTUAL participants

Conditions

COVID-19

Interventions

EuCorVac-19

BIOLOGICAL

ChAdOx1 nCoV-19

BIOLOGICAL

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162

COVID-19

View study

RECRUITINGNA

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 17, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

Inclusion Criteria

Exclusion Criteria

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate

Positron Emission Tomography (PET) Imaging of Thrombosis